Patent: 7,470,696
✉ Email this page to a colleague
Summary for Patent: 7,470,696
Title: | Tyrosine kinase inhibitors |
Abstract: | The present invention provides compounds of formula I ##STR00001## and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. |
Inventor(s): | Beaulieu; Francis (Laprairie, CA), Ouellet; Carl (Boucherville, CA), Zimmermann; Kurt (Durham, CT), Velaparthi; Upender (Cheshire, CT), Wittman; Mark D. (Wallingford, CT) |
Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
Application Number: | 11/625,973 |
Patent Claims: | see list of patent claims |
Details for Patent 7,470,696
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2023-01-03 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2023-01-03 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2023-01-03 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |